E
Erik Asmus
Researcher at Mayo Clinic
Publications - 12
Citations - 443
Erik Asmus is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 5, co-authored 9 publications receiving 302 citations.
Papers
More filters
Journal ArticleDOI
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
Wei Ding,Betsy LaPlant,Timothy G. Call,Sameer A. Parikh,Jose F. Leis,Rong He,Tait D. Shanafelt,Sutapa Sinha,Jennifer Le-Rademacher,Andrew L. Feldman,Thomas M. Habermann,Thomas E. Witzig,Gregory A. Wiseman,Yi Lin,Erik Asmus,Grzegorz S. Nowakowski,Michael J. Conte,Deborah A. Bowen,Casey N. Aitken,Daniel L. Van Dyke,Patricia T. Greipp,Xin Liu,Xiaosheng Wu,Henan Zhang,Charla R. Secreto,Shulan Tian,Esteban Braggio,Linda Wellik,Ivana N. Micallef,David S. Viswanatha,Huihuang Yan,Asher Chanan-Khan,Neil E. Kay,Haidong Dong,Stephen M. Ansell +34 more
TL;DR: The results of this study are the first to demonstrate the benefit of PD-1 blockade in CLL patients with RT, and could change the landscape of therapy for RT patients if further validated.
Journal ArticleDOI
A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer.
Ashish V. Chintakuntlawar,Jun Yin,Robert L. Foote,Jan L. Kasperbauer,Michael Rivera,Erik Asmus,Nina I. Garces,Jeffrey R. Janus,Minetta C. Liu,Daniel J. Ma,Eric J. Moore,John C. Morris,Michelle A. Neben-Wittich,Daniel L. Price,Katharine A. Price,Mabel Ryder,Kathryn M. Van Abel,Crystal Hilger,Eleyna Samb,Keith C. Bible +19 more
TL;DR: Although initially tolerated and effective in terms of locoregional disease control, disappointing survival outcomes compared to historical controls raise uncertainty that the piloted approach merits further pursuit in ATC.
Journal ArticleDOI
Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
Gerardo Colon-Otero,Valentina Zanfagnin,Xiaonan Hou,Nathan R. Foster,Erik Asmus,Andrea E. Wahner Hendrickson,Aminah Jatoi,Matthew S. Block,Carrie L. Langstraat,Gretchen E. Glaser,Tri A. Dinh,Matthew W. Robertson,John K. Camoriano,Kristina A. Butler,John A. Copland,S. John Weroha +15 more
TL;DR: Ribociclib and letrozole have promising clinical activity in relapsed ER-positive OC and EC, particularly in LGSOC and relapsedER-positive grade 1 and 2 EC.
Journal ArticleDOI
Results of a phase 2 trial of ribociclib and letrozole in patients with either relapsed estrogen receptor (ER)-positive ovarian cancers or relapsed ER-positive endometrial cancers.
Gerardo Colon-Otero,S. John Weroha,Valentina Zanfagnin,Nathan R. Foster,Erik Asmus,Andrea E. Wahner Hendrickson,Aminah Jatoi,Matthew S. Block,Carrie L. Langstraat,Gretchen E. Glaser,Tri A. Dinh,Matthew W. Robertson,John K. Camoriano,Kristina A. Butler,John A. Copland +14 more
TL;DR: The once-weekly dosing schedule for single agent aromatase inhibitor therapy with or without chemotherapy for ovarian cancer and endometrial cancers was found to be safe and effective.
Journal ArticleDOI
PD-1 Blockade with Pembrolizumab in Relapsed Low Grade Non-Hodgkin Lymphoma
Wei Ding,Betsy LaPlant,Thomas E. Witzig,Patrick B. Johnston,Joseph P. Colgan,Karen L. Rech,Jose F. Leis,Andrew L. Feldman,Rong He,Grzegorz S. Nowakowski,Erik Asmus,David J. Inwards,Luis F. Porrata,Thomas M. Habermann,Yi Lin,Gita Thanarajasingam,N. Nora Bennani,Craig B. Reeder,Donald W. Northfelt,Jeanne Palmer,Prashant Kapoor,David S. Viswanatha,Stephen M. Ansell +22 more
TL;DR: A phase 2 trial to test the efficacy of the PD-1 blocking antibody pembrolizumab in relapsed/refractory low grade NHL and found it had an acceptable safety profile.